Health authorities, and scientists, were particularly alarmed by one clinic advertising the treatment of multiple sclerosis through stem cell injections into spinal and brain fluid using lumbar injections.

Jo Flynn (Medical Board of Australia, Australia) commented: “The level of risk is unacceptable and it needs tighter regulation. The board is concerned at some of the emerging forms of treatment which are being offered outside the confines of regulated clinical trials, often for people with chronically disabling conditions.”

The Therapeutic Goods Administration began investigating the regulations this year but has not yet published any results from their review.

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.